Independent
Tenure on this board
10.2 yrs
Meeting calendar
INM · Annual meeting · Wednesday, December 17, 2025
Inmed Pharmaceuticals Inc
5 nominees · 4 ballot items.
The meeting covers the presentation of financial statements (no vote), election of five directors, appointment of CBIZ CPAs P.C. as auditor, and SEPA share issuance (approval).
Market cap
—
1Y TSR
-7.9%
Board grade
C-
Record date
Oct 22, 2025
Filing
DEF 14A
Meeting concluded · Dec 17, 2025
Follow how the vote landed and what changed on Inmed Pharmaceuticals Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot4
- 1
PRESENTATION OF FINANCIAL STATEMENTS
ManagementThe audited consolidated financial statements for the fiscal year ended June 30, 2025, and related auditor’s report will be presented to Shareholders; no vote will be taken.
- 2
ELECTION OF DIRECTORS
ManagementBoard: FORThe Board proposes to nominate five individuals to stand for election as directors to hold office until the next annual meeting; directors to be elected by a plurality; majority voting policy for uncontested election.
- 3
APPOINTMENT OF AUDITOR
ManagementBoard: FORTo appoint CBIZ CPAs P.C. as the auditor and independent registered public accounting firm of the Company for the ensuing year; remuneration to be fixed by the Board; CBIZ has been the auditor since June 12, 2025.
- 4
SEPA SHARE ISSUANCE PROPOSAL
ManagementBoard: FORApproval of the potential issuance of 20% or more of the Company’s issued and outstanding common shares under the standby equity purchase agreement with YA II PN, Ltd. (Yorkville), including the minimum price and Nasdaq-rule considerations; dilution and current share cap implications.
Director elections
Nominees on the ballot5
Independent
Tenure on this board
4.3 yrs
Also a director at
Medicinova Inc (MNOV)
Independent
Tenure on this board
1.1 yrs
Independent
Tenure on this board
1.1 yrs
Not independent
Tenure on this board
10.9 yrs
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | ADAR1 Capital Management, LLC | 14.6% | 800,000 | $1M |
| 2 | Vivo Capital, LLC | 14.5% | 798,377 | $1M |
| 3 | Squadron Capital Management LLC | 5.9% | 325,000 | $504K |
| 4 | Ikarian Capital, LLC | 4.5% | 245,025 | $380K |
| 5 | Ursa Fund Management, LLC | 2.3% | 125,800 | $195K |
| 6 | MONTANOVA CAPITAL, LLC | 1.8% | 100,000 | $155K |
| 7 | BOOTHBAY FUND MANAGEMENT, LLC | 1.4% | 74,244 | $115K |
| 8 | SABBY MANAGEMENT, LLC | 0.8% | 44,970 | $70K |
| 9 | Venrock Adviser, LLC | 0.6% | 32,685 | $51K |
| 10 | CITADEL ADVISORS LLC | 0.5% | 26,084 | $40K |
Filings
Inmed Pharmaceuticals Inc proxy statements and SEC reports
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Inmed Pharmaceuticals Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Cardinal Health IncCAH
Annual meeting·Nov 12, 2026·$63.4B
Wave Life Sciences IncWVE
Annual meeting·Nov 12, 2026·$686M
Impact Biomedical IncIBO
Special meeting·Nov 13, 2026·$467M
Korsana Biosciences IncKRSA
Special meeting·Nov 13, 2026·$1.4B
Angiodynamics IncANGO
Annual meeting·Nov 17, 2026·$510M
Resmed IncRMD
Annual meeting·Nov 18, 2026·$33.2B
Reference
Frequently asked questions
- When is the Inmed Pharmaceuticals Inc 2025 annual meeting?
- Inmed Pharmaceuticals Inc (INM) holds its 2025 annual shareholder meeting on Wednesday, December 17, 2025.
- What is the record date for the Inmed Pharmaceuticals Inc 2025 meeting?
- The record date for the Inmed Pharmaceuticals Inc 2025 meeting is Wednesday, October 22, 2025. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Inmed Pharmaceuticals Inc's 2025 meeting?
- The board is presenting 5 director nominees at the Inmed Pharmaceuticals Inc 2025 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Inmed Pharmaceuticals Inc 2025 meeting?
- Shareholders will vote on 4 proposals at the Inmed Pharmaceuticals Inc 2025 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.